NEW YORK (GenomeWeb News) – Swiss diagnostics lab Viollier has obtained rights to offer Epigenomics' molecular test for colorectal cancer detection as a service to patients in Europe beginning July 1.
Berlin-based Epigenomics said that the test is based on its mSEPT9 biomarker and is the first ever blood-based test for colorectal cancer to be offered in Europe. It said that it expects other diagnostic labs in Europe to offer mSEPT9 testing "in due course."
In addition, Epigenomics said that mSEPT9 testing in the US would initially be offered by Quest Diagnostics.
"Blood sampling is easy and convenient for both the patient and the doctor," Edouard Viollier, chairman of Viollier's board of directors, said in a statement. "We believe that this could be the future of non-invasive colorectal cancer screening and key to increasing compliance to screening programs."